Last Updated: November 16, 2026

Investigational Drug Information for Asoprisnil

« Back to Dashboard


What is the development status for investigational drug Asoprisnil?

Asoprisnil is an investigational drug.

There have been 15 clinical trials for Asoprisnil. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2003.

The most common disease conditions in clinical trials are Myofibroma, Leiomyoma, and Menorrhagia. The leading clinical trial sponsors are Abbott, Jenapharm GmbH & Co. KG, and TAP Pharmaceutical Products Inc.

Recent Clinical Trials for Asoprisnil
TitleSponsorPhase
Study of Asoprisnil in the Treatment of Uterine Fibroids.AbbottPhase 3
Safety of Treatment of Uterine Fibroids With AsoprisnilAbbottPhase 3
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine FibroidsAbbottPhase 3

See all Asoprisnil clinical trials

Clinical Trial Summary for Asoprisnil

Top disease conditions for Asoprisnil
Top clinical trial sponsors for Asoprisnil

See all Asoprisnil clinical trials

Asoprisnil Development Update, Patent Outlook, and Market Projection

Last updated: September 24, 2026

Asoprisnil is a discontinued selective progesterone receptor modulator (SPRM) that was investigated primarily for uterine fibroids and endometriosis. Its clinical program did not reach approval, no commercial product was launched, and no active market exists for asoprisnil. The market projection is therefore zero for approved-product sales unless a sponsor revives the molecule through a new clinical and regulatory program.

What is the current development status of asoprisnil?

Asoprisnil, also known as J867, is no longer an active clinical-stage drug candidate in the public development pipeline.

TAP Pharmaceuticals developed asoprisnil as an oral SPRM for women with symptomatic uterine fibroids. Clinical studies evaluated its ability to reduce heavy menstrual bleeding and fibroid-related symptoms without inducing the full estrogen-deprivation profile associated with gonadotropin-releasing hormone agonists.

The program reached mid- and late-stage clinical development but was discontinued after endometrial changes were observed during longer-term treatment. Asoprisnil was never approved by the U.S. Food and Drug Administration, European Medicines Agency, or another major regulatory authority.

Development attribute Status
Active ingredient Asoprisnil, J867
Drug class Selective progesterone receptor modulator
Primary indication Symptomatic uterine fibroids
Other investigated use Endometriosis
Route Oral
Lead developer TAP Pharmaceuticals
Highest known development stage Phase III
FDA approval None
Commercial launch None
Current marketed product None
Biosimilar relevance None
Generic competition None because no approved reference product exists
Development status Discontinued

Clinical publications reported reductions in uterine bleeding and fibroid volume in women treated with asoprisnil. The clinical benefit was offset by endometrial findings that created a regulatory and safety barrier to continued development. The program did not produce a successful risk-management strategy or an approved label.

Why was asoprisnil discontinued?

The principal development problem was treatment-associated endometrial pathology.

SPRMs act on progesterone receptors in a tissue-selective manner. In the uterus, this mechanism can suppress bleeding and alter fibroid biology, but it can also produce endometrial thickening and other endometrial changes. In asoprisnil studies, investigators observed endometrial findings that required further assessment and limited the ability to establish a commercially acceptable long-term safety profile.

TAP Pharmaceuticals discontinued the uterine-fibroid development program in 2005 after discussions concerning the endometrial findings. The discontinuation occurred before submission of a successful new drug application.

The development outcome was materially different from that of ulipristal acetate, another SPRM that reached approval in some jurisdictions for uterine fibroids but later faced severe liver-safety restrictions and withdrawal or suspension in several markets. Asoprisnil never progressed to the commercial-risk stage because it did not obtain initial regulatory approval.

What clinical evidence supported asoprisnil?

Uterine fibroid trials

Phase II studies found that asoprisnil reduced menstrual bleeding and improved fibroid-related symptoms. Some trials also reported decreases in fibroid volume and uterine volume.

One randomized clinical study evaluated several asoprisnil doses over approximately 12 weeks in premenopausal women with symptomatic uterine leiomyomata. The drug produced clinically meaningful reductions in bleeding compared with placebo and showed dose-related effects on fibroid and uterine measurements. The findings supported advancement into longer-term and Phase III development (Chwalisz et al., 2007).

The clinical profile was commercially attractive because uterine fibroids affect a large population and create demand for non-surgical treatments. A successful oral therapy could have competed with GnRH agonists, GnRH antagonists, hormonal contraceptives, tranexamic acid, uterine artery embolization, and surgery.

Endometriosis research

Asoprisnil was also studied for endometriosis-related pain and disease activity. The mechanism was biologically relevant because progesterone-receptor modulation can suppress endometrial tissue activity. The development program, however, did not produce an approved endometriosis indication.

No efficacy result can support a current commercial forecast because the molecule lacks regulatory approval and no sponsor has reactivated the program.

When did asoprisnil lose exclusivity?

Asoprisnil did not have an approved-product exclusivity period in the United States.

FDA regulatory exclusivity is generally triggered by approval, not by the mere existence of a clinical program. Because asoprisnil never received FDA approval, it did not obtain:

  • New chemical entity exclusivity.
  • Five-year Hatch-Waxman exclusivity.
  • Three-year clinical-investigation exclusivity.
  • Orphan-drug exclusivity.
  • Pediatric exclusivity.
  • An Orange Book reference-product listing.

Patent protection, if still present for particular compounds, formulations, or uses, would not create a viable commercial market without regulatory approval. Patent expiration also would not automatically permit generic launch because there is no FDA-approved asoprisnil reference product against which an ANDA could be filed.

What patents protect asoprisnil?

Asoprisnil was developed within a broader SPRM patent field that included composition-of-matter, analog, formulation, and therapeutic-use claims. Public patent records associated with SPRMs and uterine-fibroid treatment include portfolios from companies such as TAP Pharmaceuticals and related pharmaceutical entities.

The commercially relevant distinction is between patent protection and an active drug product:

Patent category Commercial relevance to asoprisnil
Composition of matter Potentially protected the molecule or chemical family during development
Pharmaceutical composition Could cover oral dosage forms and excipients
Method of treatment Could cover treatment of uterine fibroids, endometriosis, or bleeding
Dosing regimen Could cover dose, cycle length, or intermittent administration
Manufacturing process Could restrict a particular synthesis route
Regulatory exclusivity None because no product approval occurred
Orange Book listing None identified for an approved asoprisnil product

A complete current patent-clearance conclusion requires a live search of national patent registers, assignment records, maintenance-fee status, terminal disclaimers, and patent-term-adjustment data. The available development history supports a narrower business conclusion: patent rights did not translate into a launched asoprisnil product.

What is the Orange Book status of asoprisnil?

Asoprisnil has no FDA Orange Book status as an approved drug.

There is no approved asoprisnil reference listed in the Orange Book, no FDA-approved label, and no established U.S. generic pathway tied to an asoprisnil product. The absence of an Orange Book listing also means there is no standard Paragraph IV litigation framework directed at an approved asoprisnil reference drug.

Were there Paragraph IV challenges or patent litigation?

No commercially significant Paragraph IV challenge has been associated with asoprisnil because the molecule never reached an approved reference-product stage.

The same applies to Hatch-Waxman patent litigation. Generic applicants typically challenge listed patents after an innovator files an NDA and the FDA lists patents in the Orange Book. Asoprisnil did not generate that sequence.

Publicly documented development concerns centered on clinical safety and endometrial findings rather than generic patent litigation. No major settlement agreement involving a generic launch of asoprisnil has been established in the public development record.

What is the biosimilar and generic risk for asoprisnil?

Biosimilar risk is not applicable. Asoprisnil is a synthetic small molecule, not a biologic.

Generic risk is also inactive in practical terms. A generic manufacturer could theoretically develop an asoprisnil product, but it would need an approved regulatory pathway, a reference-product strategy, manufacturing controls, clinical or bridging evidence where required, and a commercial sponsor willing to assume the endometrial-safety risk.

The more important risk is development risk, not patent erosion. A revived program would face:

  1. Reassessment of endometrial safety.
  2. A requirement for longer-duration exposure data.
  3. Dose and treatment-cycle optimization.
  4. Potential endometrial monitoring in the label.
  5. Competition from newer GnRH antagonists.
  6. A need to demonstrate a benefit-risk profile superior to existing medical and surgical options.

How does asoprisnil compare with current uterine-fibroid therapies?

Asoprisnil would enter a more competitive market than the one that existed when its Phase III program was active.

Therapy Regulatory position Main commercial strength Key limitation
Asoprisnil Not approved Oral SPRM mechanism; bleeding control in trials Endometrial safety; discontinued
Relugolix combination therapy Approved in the U.S. for uterine fibroids Oral, non-surgical treatment with add-back therapy Hypoestrogenic risks and duration considerations
Elagolix combination therapy Approved in the U.S. for uterine fibroids Oral GnRH-antagonist treatment Bone and hormonal adverse-effect management
Uterine artery embolization Established procedure Non-hormonal, uterus-sparing intervention Procedure-related risks and fertility considerations
Myomectomy Established surgery Removes fibroids directly Operative risk and recurrence
Hysterectomy Definitive treatment Eliminates recurrence risk Loss of fertility and major surgery
Ulipristal acetate Restricted or withdrawn in several markets SPRM efficacy in selected settings Severe liver-injury concerns

Current oral GnRH-antagonist combinations would create a substantial competitive hurdle for any asoprisnil revival. A new sponsor would need to show a meaningful differentiation in bleeding control, fibroid-volume reduction, fertility preservation, tolerability, dosing convenience, or long-term safety.

What is the market projection for asoprisnil?

The base-case market projection is zero because asoprisnil has no approved product, no active commercial supply, and no publicly established development sponsor.

Base case: discontinued program

Projection period Expected commercial revenue
Current year $0
Next 3 years $0
Next 5 years $0
Longer term without revival $0

These figures reflect product status, not the theoretical size of the uterine-fibroid treatment market.

Revival case

A revival would require a new sponsor to obtain rights, establish current intellectual-property freedom to operate, complete clinical development, and secure approval. The timing would likely resemble a new clinical program rather than a simple patent-based launch. A realistic commercial launch would require several years after program reactivation, with substantial development spending and regulatory risk.

Even if successfully revived, the addressable market would be constrained by:

  • Competition from approved oral GnRH antagonists.
  • The need for endometrial surveillance.
  • The historical safety signal.
  • Physician familiarity with current therapies.
  • Payer requirements for step therapy.
  • Surgical alternatives with established reimbursement.
  • The absence of an existing brand, sales force, and manufacturing network.

No defensible revenue estimate exists for a hypothetical revival without a defined sponsor, dose, indication, trial design, development budget, launch geography, and regulatory strategy.

What manufacturing and intellectual-property barriers would affect revival?

Asoprisnil is a synthetic small molecule, so manufacturing complexity would likely be lower than for a biologic. The principal manufacturing requirements would include validated chemical synthesis, impurity control, stability data, solid-state characterization, and reproducible oral dosage-form production.

The larger barriers are regulatory and clinical:

  • Reconstructing the complete nonclinical and clinical safety database.
  • Defining the significance of prior endometrial findings.
  • Establishing an acceptable monitoring protocol.
  • Demonstrating long-term safety.
  • Confirming dose selection.
  • Obtaining current-country regulatory approvals.
  • Protecting any new formulation, dosing, or treatment method with patent claims.

A reformulated or intermittent-dose product could create new patent opportunities, but those claims would not remove the underlying need to resolve the molecule’s historical safety concerns.

What licensing or acquisition activity involves asoprisnil?

No current licensing deal, acquisition, or relaunch partnership has established a commercial asoprisnil program. The original development was associated with TAP Pharmaceuticals, a joint venture of Abbott Laboratories and Takeda Pharmaceutical Company. TAP’s corporate assets and products were later reorganized through the parent companies, but that corporate history did not result in an approved asoprisnil product.

There is no identified active licensee marketing asoprisnil or advancing it through clinical development.

Key Takeaways

  • Asoprisnil is a discontinued oral SPRM for uterine fibroids and endometriosis.
  • TAP Pharmaceuticals advanced the molecule to Phase III.
  • Endometrial changes prevented successful development and approval.
  • The FDA has never approved asoprisnil.
  • No Orange Book listing, approved reference product, Paragraph IV dispute, biosimilar program, or generic market exists.
  • Commercial revenue is currently projected at zero.
  • A revival would require a new sponsor, renewed clinical development, a regulatory strategy for endometrial safety, and differentiation from approved GnRH-antagonist therapies.
  • Patent rights alone do not create a viable commercial opportunity without regulatory approval.

FAQs About Asoprisnil

Is asoprisnil still available by prescription?

No. Asoprisnil is not an approved prescription product and is not commercially available through standard pharmacy channels.

Did asoprisnil receive FDA approval?

No. The FDA did not approve asoprisnil for uterine fibroids, endometriosis, or another indication.

Is asoprisnil the same as ulipristal acetate?

No. Both are SPRMs, but they are different active ingredients. Ulipristal acetate reached approval in some markets, while asoprisnil did not.

Could a company restart asoprisnil development?

Yes, in principle, but a restart would require a new sponsor, current regulatory engagement, renewed clinical evidence, and resolution of the historical endometrial-safety concerns.

Does asoprisnil have generic competition?

No. There is no approved U.S. asoprisnil reference product and no established generic market.

References

  1. Chwalisz, K., Larsen, L., Mattia-Goldberg, C., Edmonds, A., Elger, W., & Winkel, C. (2007). A randomized, placebo- and active-controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility, 87(6), 1399-1412.

  2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  3. American College of Obstetricians and Gynecologists. (2021). Management of symptomatic uterine leiomyomas. ACOG Practice Bulletin.

  4. Donnez, J., & Dolmans, M.-M. (2016). Uterine fibroid management: From the present to the future. Human Reproduction Update, 22(6), 665-686.

  5. U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Asoprisnil clinical studies. National Institutes of Health.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.